Aphasic Variant of Alzheimer Disease
Neurol 87:1337-1343, Rogalski, E.,et al, 2016
The Logopenic/Phonological Variant of Primary Progressive Aphasia
Neurol 71:1227-1234, Gorno-Tempini,M.L.,et al, 2008
Neuropsychological Detection and Characterization of Preclinical Alzheimer's Disease
Neurol 45:957-962, Jacobs,D.M.,et al, 1995
Posterior Cortical Atrophy:Neuropathologic Correlations
Arch Neurol 51:269-274, Victoroff,J.,et al, 1994
Pick's Disease Versus Alzheimer's Disease:A Comparison of Clinical Characteristics
Neurol 43:289-292, Mendez,M.F.,et al, 1993
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Patients with Rosacea have Increased Risk of Dementia
Ann Neurol 79:921-928, Egeberg, A.,et al, 2016
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Dementia: Timely Diagnosis and Early Intervention
BMJ 350:h3029, Robinson, L.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Fracture as an Independent Risk Factor of Dementia
Medicine 93:e188, Tsai, C.H.,et al, 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Should Patients with Dementia who Wander be Electronically Tagged? Yes
BMJ 346:f3603, McShane, R., 2013
Is There a Link Between Open-Angle Glaucoma and Dementia?: The Three-City-Alienor Cohort
Ann Neurol 74:171-179, Helmer, C.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Antidepressant Treatment in Alzheimers Disease
Lancet 378:375-378, Brodaty, H., 2011
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
The Older Adult Driver with Cognitive Impairment: "Its a Very Frustrating Life"
JAMA 303:1632-1641, 1642, 1660, Carr,D.B. &Ott,B.R., 2010
Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:1316-1324, Iverson,D.J., et al, 2010